Health News

A regulatory bias against taking oral anti-cancer medications with food places many patients at increased risk for an overdose and forces them to “flush costly medicines down the toilet,” argues Mark Ratain, MD, an authority on cancer-drug dosing. In a commentary published early online Sept. 19 in the Journal of Clinical Oncology, Ratain, the Leon O…

Read more

Filed under: Pharmacy News
Tags: cancer, Drug, medicine, Oncology, Online, Pharmacy

Related posts

• Æterna Zentaris Zentaris requests EMA Scientific Advice for Phase 3 program with perifosine (0)
  Æterna Zentaris Inc., a late-stage drug development company specialized in oncology and endocrine therapy, today announced that it has requested Scientific Advice from the European Medicines Agency (EMA) to assure the acceptability of the recently initiated Phase 3 programs for the development of its lead anticancer compound, perifosine, in its two lead indications, multiple myeloma [...]
  
  
• Project Zero Delay Accelerates Drug’s Path To Clinical Trial (0)
  A phase I clinical trial enrolled its first patient only two days after U.S. Food and Drug Administration clearance of the experimental drug for a first-in-human cancer trial, a milestone that normally takes three to six months. Investigators from The University of Texas M. D. Anderson Cancer Center and pharmaceutical company AstraZeneca have reported their [...]
  
  
• NSAIDs like ibuprofen slow the spread of breast cancers (0)
  Published online on Aug. 7, 2011, the journal Nature Medicine reports that non-steroidal anti-inflammatory drugs including ibuprofen reduce the severity of postpartum breast cancers in animal models. Read more [tags] Pharmacy News [/tags]
  
  
• Identifying a specific molecular signature can help customize cancer treatment (0)
  A molecular signature that helps account for the aggressive behavior of a variety of cancers such as pancreatic, breast and melanoma may also predict the likelihood of successful treatment with a particular anti-cancer drug. The finding, which could lead to a personalized approach to treatment for a variety of solid tumors that are currently resistant [...]
  
  
• Aeterna Zentaris’ AEZS-108 receives orphan medicinal product designation for ovarian cancer in Europe (0)
  Aeterna Zentaris Inc. a late-stage drug development company specialized in oncology and endocrinology, today announced that it has received a positive opinion for orphan medicinal product designation from the Committee for Orphan Medicinal Products (COMP) of the European Medicines Agency, for its compound AEZS-108 for the treatment of ovarian cancer. AEZS-108, the Company's doxorubicin targeted [...]